Panel: Focus on IP, Not Cash When Inking Multi-Asset Deals
SAN FRANCISCO – The final day of the 2011 BIO Investor Forum started with some encouraging news: The discovery-stage deal is alive and well for biotech.
In the last two months alone, BioWorld Today has reported on several deals, including Ipsen SA's multi-asset deal with Syntaxin Ltd. for botulinum toxin drugs; Merck Serono SA's potential $691 million inflammatory disease antibody collaboration with F-Star GmbH; and Merck & Co. Inc. becoming the first major commercialization partner in an early stage deal for Zymeworks Inc.'s bi-specific antibody technology.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter